NCT04497116 2025-10-21
TRESR
Repare Therapeutics
Phase 1/2 Completed
Clinical Trials
10 trialsNCT03077607 2021-06-30
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT02997176 2021-02-25
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
Pfizer
Phase 1 Completed
NCT01989546 2021-02-23
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02392793 2021-02-09
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02997163 2021-01-05
An Open-Label Pharmacokinetics and Safety Study of Talazoparib
Pfizer
Phase 1 Completed
NCT02358200 2020-01-10
Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer
University of California, San Francisco
Phase 1 Terminated
NCT03042910 2019-12-17
A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT03070548 2018-12-17
A Study of Talazoparib in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT02567396 2017-04-24
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Withdrawn